Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Hemagen Diagnostics's Revenue for the
three
months ended in Sep. 2012 was $0.88 Mil. Hemagen Diagnostics's average Accounts Receivable for the
three
months ended in Sep. 2012 was $0.59 Mil.
Hence, Hemagen Diagnostics's Receivables Turnover for the
three
months ended in Sep. 2012 was 1.49.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Hemagen Diagnostics Receivables Turnover Related Terms
Hemagen Diagnostics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Hemagen Diagnostics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HMGN vs OBMP, NSPX, ATRX: Receivables Turnover Comparison
For the Biotechnology subindustry, Hemagen Diagnostics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hemagen Diagnostics Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hemagen Diagnostics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Hemagen Diagnostics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hemagen Diagnostics (HMGN) has a Receivables Turnover of 1.49 as of Sep. 2012. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Hemagen Diagnostics and its competitors.
Is Hemagen Diagnostics' Receivables Turnover too high?
Hemagen Diagnostics' current Receivables Turnover is 1.49. The Biotechnology industry median Receivables Turnover is 5.28. Hemagen Diagnostics' value of 1.49 is 71.8% below this industry median.
How does Hemagen Diagnostics' Receivables Turnover compare to OBMP and NSPX?
Hemagen Diagnostics' Receivables Turnover of 1.49 can be compared against companies in the Biotechnology industry. The industry median Receivables Turnover is 5.28. Hemagen Diagnostics' value of 1.49 is 71.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 850 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hemagen Diagnostics's current Receivables Turnover of 1.49 is 71.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Hemagen Diagnostics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hemagen Diagnostics's current Receivables Turnover is 1.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemagen Diagnostics stock overvalued right now?
Hemagen Diagnostics (HMGN) has a current Receivables Turnover of 1.49. The current Receivables Turnover is 1.49 and 71.8% below the Biotechnology industry median of 5.28. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Hemagen Diagnostics (HMGN), the current Receivables Turnover is 1.49 as of Sep. 2012. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hemagen Diagnostics Inc is a biotechnology company. It develops, manufactures and markets Food and Drug Administration cleared proprietary medical diagnostic test kits and components. The company's Virgo line of Immunoassays are used to aid in the diagnosis of autoimmune and infectious diseases and acute-phase proteins. The assays utilize multiple technologies including ELISA, immunofluorescence (IFA) and hemagglutination (HA). Its products include ANA Screen ELISA 96 Test System, Rubella IgG ELISA 96 Test System, AMA IFA 48 Test System and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HMGN has been successfully added to your 
